Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular Dystrophies (WANTED)

March 2, 2026 updated by: Centre Hospitalier Universitaire Dijon

Facioscapulohumeral muscular dystrophy (FSH) is one of the most common genetic myopathies in adults. It is characterised by progressive asymmetric muscular atrophy affecting the skeletal muscles of the face, upper limbs and then lower limbs, causing problems with walking, which is one of the most frequent complaints of these patients. In fact, 20% of people with FSH require a wheelchair from the age of 60. To date, scientific research into FSH has focused mainly on the molecular level, enabling potential therapeutic targets to be identified. Trials of gene therapies and other drug therapies are gradually emerging, with the aim of having a positive impact on these people's functional abilities, particularly walking difficulties. However, few studies have looked at the functional impact of FSH on these people, and in particular at the specific analysis of their walking ability In France, the functional assessment of FSH is carried out using a clinical reference scale called the Motor Function Measurement (MFM), the D1 sub-score of which studies items relating to standing and transfers. However, this scale does not objectively and specifically study gait disorders, and its application requires a great deal of time (at least 30 minutes) and specific training leading to certification, limiting its use in practice almost exclusively to centres of expertise and reference for neuromuscular diseases. The NeuroMuscular Score-D1 (NM-score D1), linked to the MFM D1 sub-score, is the only French scale validated in the literature for assessing the severity of gait disorders in FSH, but it is very little used in current practice because it is little known and only descriptive.

Certain functional tests of walking ability (so-called "short-duration" tests such as the 10-metre test at comfortable and fast speeds, the Time Up and Go test [TUG], and so-called "long-duration" tests such as the 6-minute test [TM6]) exist and are much simpler to use in clinical practice, do not require certification and can be carried out in a shorter time. However, to date there is no consensus on the use of these walking tests in FSH. Furthermore, their ecological capabilities (i.e. their ability to reflect what happens in real life) are not really known. In this sense, technological developments in quantified gait analysis (QGA) could help to assess locomotion disorders (of neurological, muscular or joint origin, etc.) more effectively and objectively. A more consensual use of gait tests in FSH with the use of innovative connected tools that are accessible (e.g. use of inertial units to measure spatio-temporal gait parameters during gait tests) in clinical routine would make it possible to obtain new gait analysis data to explore gait disorders more specifically and in a simple, rapid and objective manner, and thus improve and optimise the day-to-day monitoring of these patients by a large proportion of healthcare professionals.

The aim of the WANTED project is therefore to assess the value of quick and easy walking tests as part of the functional evaluation of patients with FSH by studying the correlation between the data obtained with these walking tests and that obtained with the MFM, the reference method, and also with data obtained in real-life conditions (e.g. physical activity time via actimetry).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patient :

  • Adult ;
  • Having given written consent;
  • With an established molecular genetic diagnosis of FSH;
  • Able to understand the instructions for carrying out the various tests;
  • Able to walk for at least 6 minutes, even intermittently;

Exclusion Criteria:

Patient :

  • Not affiliated to or not benefiting from a social security scheme;
  • With one or more cardiorespiratory contraindications to a 6-minute test;
  • With another neuro-orthopaedic history (other than FSH) that could significantly compromise walking ability;
  • With cognitive problems preventing them from performing standardised tasks;
  • Under legal protection (curatorship, guardianship).
  • Who are subject to a legal protection measure;
  • Pregnant, parturient or breast-feeding woman;
  • Unable to benefit from longitudinal follow-up (D15 and M6).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patient
Other: Walk tests

Performance of the following walking tests using inertial measurement units: TUG; 10 m test at a comfortable and fast speed and TM6 (according to the recommendations of the American Thoracic Society).

At the end of each walking test, measurement of the difficulty of exertion using the Borg scale.

Other: ecological (real-life) assessment of walking ability
Delivery of an actimeter, inertial units and logbook for ecological assessment (in real life) of walking ability for 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Average walking speed during TM6
Time Frame: Through study completion, on average of 30 month
Through study completion, on average of 30 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire Dijon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 3, 2024

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

September 13, 2024

First Submitted That Met QC Criteria

September 13, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 3, 2026

Last Update Submitted That Met QC Criteria

March 2, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HADOUIRI AOI 2022

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Facioscapulohumeral Dystrophy

Clinical Trials on Walk tests

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe